Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

12.2%

12 terminated/withdrawn out of 98 trials

Success Rate

86.4%

-0.1% vs industry average

Late-Stage Pipeline

38%

37 trials in Phase 3/4

Results Transparency

62%

47 of 76 completed trials have results

Key Signals

47 with results11 terminated

Enrollment Performance

Analytics

N/A

32(35.2%)

Phase 4

23(25.3%)

Phase 3

14(15.4%)

Phase 2

13(14.3%)

Phase 1

7(7.7%)

Early Phase 1

2(2.2%)

91Total

N/A(32)

Phase 4(23)

Phase 3(14)

Phase 2(13)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (98)

Showing 20 of 98 trials

NCT00621634Phase 2Withdrawn

Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia

Role: collaborator

NCT00565617Not ApplicableActive Not Recruiting

Epidural Cortical Stimulation for Depression

Role: collaborator

NCT01545999Not ApplicableActive Not Recruiting

Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia

Role: collaborator

NCT04657432Not ApplicableActive Not Recruiting

Brief, High-dose rTMS for Depression

Role: collaborator

NCT00288353Phase 3Terminated

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

Role: collaborator

NCT00373672Phase 4Completed

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

Role: collaborator

NCT00306475Phase 4Completed

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

Role: collaborator

NCT00590265Not ApplicableActive Not Recruiting

Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression

Role: collaborator

NCT00727103Phase 4Completed

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

Role: collaborator

NCT00431574Not ApplicableCompleted

Antipsychotic Medication Extended Dosing Study

Role: collaborator

NCT01521026Not ApplicableCompleted

Cognitive Training for Patients With Schizophrenia

Role: collaborator

NCT01881763Phase 4Completed

Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

Role: collaborator

NCT00591318Phase 1Terminated

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

Role: collaborator

NCT00611572Phase 1Completed

GABA-glutamate Interactions and Psychosis

Role: collaborator

NCT00700596Early Phase 1Completed

Effects of Salvinorin A in Healthy Controls

Role: collaborator

NCT00467753Not ApplicableCompleted

Oxcarbazepine Versus Placebo in Childhood Autism

Role: collaborator

NCT00575328Phase 3Terminated

Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females

Role: collaborator

NCT02909504Phase 4Terminated

Gao NARASD Lithium Study

Role: collaborator

NCT00291226Phase 2Completed

Glycine vs Placebo for the Schizophrenia Prodrome

Role: collaborator

NCT01337687Not ApplicableCompleted

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

Role: collaborator